Pacer Advisors
ZNTL icon

Pacer Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Pacer Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-953
Closed -$3.9K – 2716
2024
Q2 		$3.9K Sell
953
-433
-31% -$4.84K ﹤0.01% 3655
2024
Q1 		$21.8K Buy
+1,386
New +$19.1K ﹤0.01% 3429
2021
Q2 		– Sell
-1,530
Closed -$66K – 1569
2021
Q1 		$66K Buy
1,530
+656
+75% +$28.2K ﹤0.01% 1400
2020
Q4 		$45K Buy
+874
New +$39.4K ﹤0.01% 1425

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Pacer Advisors's ZNTL Position: Q3 2024 in Review

Pacer Advisors sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2024, closing a stake of 953 shares — an estimated $3.9K sold.

Pacer Advisors first reported a position in ZNTL in Q4 2020 and held it in 4 quarters. The position peaked at $66K in Q1 2021. 136 funds tracked by Wall St. Rank hold ZNTL as of Q3 2024.

  • Pacer Advisors reported no remaining Zentalis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 953 Zentalis Pharmaceuticals shares in Q3 2024, an estimated $3.9K.
  • Pacer Advisors first reported a position in Zentalis Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • Pacer Advisors's Zentalis Pharmaceuticals position peaked at $66K in Q1 2021.
  • 136 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.